BioCorRx (BICX) Short term Debt (2015 - 2024)

BioCorRx has disclosed Short term Debt across 8 years of filings, most recently posting $1.2 million for Q3 2024.

• Short term Debt for Q3 2024 came in at $1.2 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2024 was $1.2 million (changed N/A YoY), and the FY2023 annual result was $999088.0, changed N/A from the prior year.
• Short term Debt came in at $1.2 million for Q3 2024 at BioCorRx, up from $865353.0 in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $3.1 million in Q2 2022 to a low of $31580.0 in Q4 2021.
• The 5-year median for Short term Debt is $2.3 million (2020), against an average of $1.8 million.
• Across the five-year window, Short term Debt rose 25.17% in 2020 and sank 98.68% in 2021, its largest moves.
• BioCorRx's Short term Debt stood at $2.4 million in 2020, then tumbled by 98.68% to $31580.0 in 2021, then soared by 9721.92% to $3.1 million in 2022, then sank by 67.79% to $999088.0 in 2023, then gained by 21.61% to $1.2 million in 2024.
• The last three Short term Debt figures came in at $1.2 million (Q3 2024), $865353.0 (Q2 2024), and $80190.0 (Q1 2024), per Business Quant data.